Home » Stocks » LOGC

LogicBio Therapeutics, Inc. (LOGC)

Stock Price: $8.36 USD -0.09 (-1.07%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $9.00 +0.64 (7.66%) Jan 15, 6:53 PM
Market Cap 266.76M
Revenue (ttm) 2.91M
Net Income (ttm) -37.19M
Shares Out 23.60M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $8.36
Previous Close $8.45
Change ($) -0.09
Change (%) -1.07%
Day's Open 8.48
Day's Range 8.26 - 8.72
Day's Volume 133,637
52-Week Range 4.06 - 11.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 month ago

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Other stocks mentioned: APRN, CACC, CLH, MGTA
Insider Monkey - 1 month ago

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our i...

Seeking Alpha - 1 month ago

Gene-editing concern LogicBio Therapeutics, Inc. has lost ~$90 million of market cap since an IND clinical hold was placed on its LB-001 candidate in February 2020. The hold was lifted in Augu...

GlobeNewsWire - 2 months ago

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery ...

GlobeNewsWire - 2 months ago

- IND for LB-001 in methylmalonic acidemia (MMA) cleared in August 2020 , with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021 - Fast Track designation for LB-00...

GlobeNewsWire - 2 months ago

Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill unmet needs for patients Fast Track designation facilitates development of new therapi...

GlobeNewsWire - 2 months ago

LEXINGTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targete...

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targete...

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targete...

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering target...

Zacks Investment Research - 3 months ago

LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in ped...

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in ped...

GlobeNewsWire - 5 months ago

– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform –

GlobeNewsWire - 5 months ago

FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Ped...

Zacks Investment Research - 5 months ago

LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

PRNewsWire - 7 months ago

NEW YORK, May 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3,...

GlobeNewsWire - 10 months ago

CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in ped...

Seeking Alpha - 11 months ago

LogicBio: A Speculative Buy For Their GeneRide Platform Based Gene Therapies

GlobeNewsWire - 11 months ago

CAMBRIDGE, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pedi...

GlobeNewsWire - 1 year ago

– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients – – Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 – – Established research collab...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pedi...

About LOGC

LogicBio Therapeutics, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collabor... [Read more...]

Industry
Biotechnology
IPO Date
Oct 19, 2018
CEO
Frederic Chereau
Employees
41
Stock Exchange
NASDAQ
Ticker Symbol
LOGC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for LOGC stock is "Strong Buy." The 12-month stock price forecast is 21.33, which is an increase of 155.14% from the latest price.

Price Target
$21.33
(155.14% upside)
Analyst Consensus: Strong Buy